In support of our findings, studies by Lublin and Poznan and Warsaw [19] identified exon 19 and 21 EGFR mutations in 10.5 % (n = 460) and 9.11 % (n = 384) of NSCLC samples, respectively. This evidence concerns the gene EGFR and non-small cell lung carcinoma.